Published guidance, NICE advice and quality standards | Guidance

Showing 281 to 290 of 872

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)	TA840	16 November 2022	16 November 2022
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)	TA838	2 November 2022	2 November 2022
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	TA836	26 October 2022	26 October 2022
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma	TA837	26 October 2022	26 October 2022
Pembrolizumab for adjuvant treatment of renal cell carcinoma	TA830	19 October 2022	19 October 2022
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids	TA832	19 October 2022	19 October 2022
Zanubrutinib for treating Waldenstrom's macroglobulinaemia	TA833	19 October 2022	19 October 2022
Fostamatinib for treating refractory chronic immune thrombocytopenia	TA835	19 October 2022	19 October 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy	TA827	5 October 2022	5 October 2022
Ozanimod for treating moderately to severely active ulcerative colitis	TA828	5 October 2022	5 October 2022